New in­vestors pool $120M to bankroll Al­lo­gene's off-the-shelf CAR-T pipeline in dri­ve to stay in the lead

It was clear from Al­lo­gene Ther­a­peu­tics’ day 1 that Arie Bellde­grun and David Chang were in no short­age of in­vestors ea­ger to back their al­lo­gene­ic CAR-T ther­a­pies: They gath­ered $300 mil­lion in short or­der from a syn­di­cate that fea­tures Pfiz­er, TPG and Vi­da Ven­tures.

The pair of Kite vets have dri­ven the point home again with a $120 mil­lion pri­vate fi­nanc­ing an­nounced Thurs­day morn­ing as they worked to fill out the full team of ex­ecs who will run the show.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.